Merck rains on Roche’s parade with double Keytruda win in squamous lung cancer

Merck already controls a big piece of the first-line non-small cell lung cancer market, and it likely just secured most of the rest. Its immunotherapy Keytruda nailed a study in previously untreated p…
Read the full story: FiercePharma: Pharma